Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Seer Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Seer (SEER – Research Report), Rocket Pharmaceutical...

Market Cap	$123.85M	P/E Ratio	NaN
52W High	$2.63	52W Low	$1.62
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	0.0%	52W Position	34.8%
Overall Score	39	Value Score	60
Quality Score	--	Technical Score	18

EPS Current Est	$NA	EPS Next Est	$NA
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SEER	$1.97	+1.55%	166.36K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SEER	$1.97	+1.5%	166.36K
3
4
5
6

SEER

SEER

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Seer Inc. Data in Excel

Get Seer Inc. Data in Excel